Journal of Alzheimer's Disease

Startpagina
Nederland
Amsterdam
Journal of Alzheimer's Disease

An international multidisciplinary journal The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor.

JAD is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease. Editor-in-Chief
George Perry, PhD
University of Texa

s at San Antonio
USA
Tel: +1.210.458.8660
Fax:+1.210.458.5658
Email: george.perry@utsa.edu
ORCID iD: 0000-0002-6547-0172

To view the full list of the Editorial Board, please visit: http://j-alz.com/board. JAD is a member of the Neuroscience Peer Review Consortium (http://nprc.incf.org). The Consortium is an alliance of neuroscience journals that have agreed to accept manuscript reviews from each other. Abstracting/Indexing

Biological Abstracts
BIOSIS Previews
CAB Abstracts
CAB Health
Chemical Abstracts Service (CAS)
CSA Biological Sciences
CSA Illumina
CSA Illustrata Natural Sciences
CSA Neurosciences Abstracts
e-psyche database
EBSCO database
Embase
EMCare
Index Copernicus
Index Medicus
Journal Citation Reports/Science Edition
MEDLINE
Neuroscience Citation Index
Prous Science Integrity
PsycInfo
PubMed
PubsHub
Science Citation Index Expanded (SciSearch)
Scopus

Audience

JAD's targeted audience is comprised of basic science researchers and clinicians in the areas of Alzheimer's disease and related disorders.

13/05/2026

Neuroinfectious Diseases Research Workshop: Advancing Translational Science and Clinical Innovation

13/05/2026

The burden of Alzheimer’s disease is one of the greatest healthcare challenges of this century.3-5 More than 100 million people worldwide are estimated to suffer from symptomatic AD, including the prodromal stage of the disease, also known as mild cognitive impairment or MCI.4 The expected increas...

13/05/2026

/PRNewswire/ -- Richard I. Horowitz, MD, and the MSIDS Research Foundation published findings today in the Journal of Alzheimer's Disease Reports demonstrating...

13/05/2026

This Medical Detective Substack will likely be one of the most important ones I will ever write and publish in my entire medical career.

13/05/2026

Drugmakers, influencers, and industry-funded advocacy groups are pushing Alzheimer’s screenings that could label millions of Americans as sick — despite shaky science and dangerous treatments.

12/05/2026

The Alzheimer’s Association welcomes FDA approval of the first non-antipsychotic treatment for disease-related agitation, Auvelity® (dextromethorphan-bupropion).

11/05/2026

Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.

11/05/2026

Philanthropy Funnels $261 Million into Parkinson’s Research Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Facebook X LinkedIn Back to the Top 08 May 2026 On April 28, Aligning Science Across Parkinson’s, ak...

11/05/2026

FDA Delays Decision on Subcutaneous Leqembi Starting Dose Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Facebook X LinkedIn Back to the Top 08 May 2026 The U.S. Food and Drug Administration has delayed a decisi...

11/05/2026

Microglia: Must-Have for Plaque Clearance With Amyloid Immunotherapy Go to another part Series - AD/PD™ 2026: Advances in Science & Therapy: Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Facebook X LinkedIn B...

11/05/2026

Looking for New Disease Markers? Try CSF, Not Plasma Quick Links Article Comments References Further Reading Tools Add to my Library Follow Comments Share How would you like to share? Facebook X LinkedIn Back to the Top 05 May 2026 Because blood is so easy to sample, scientists like to screen this b...

Adres

Nieuwe Hemweg 6B
Amsterdam
1013BG

Telefoon

+31 20 688 3355

Website

http://j-alz.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Journal of Alzheimer's Disease nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.